ישראל - עברית - Ministry of Health

gilead sciences israel ltd - anti-cd19 car t cells - anti-cd19 car t cells

ישראל - עברית - Ministry of Health

kamada ltd, israel - viable salmonella typhi ty21a cells - viable salmonella typhi ty21a cells

ישראל - עברית - Ministry of Health

teva israel ltd - filgrastim - תמיסה להזרקה\אינפוזיה - filgrastim 0.6 mg/ml - filgrastim - filgrastim - tevagrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of tevagrastim are similar in adults and children receiving cytotoxic chemotherapy. tevagrastim is indicated for the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc). in patients children or adults with severe congenital neutropenia cyclic or idiopathic neutropenia with an absolute nuetrophil count (anc) less than or equal to 0.5 x 1000000000 /l and a history of severe or recurrent infections long term administration of tevagrastim is indicated to increase neutophil count and to red

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - atezolizumab - תרכיז להכנת תמיסה לאינפוזיה - atezolizumab 60 mg/ml

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - atezolizumab - תרכיז להכנת תמיסה לאינפוזיה - atezolizumab 60 mg / 1 ml

ישראל - עברית - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

ישראל - עברית - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

ישראל - עברית - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

ישראל - עברית - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

ישראל - עברית - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.